Company / SG&A Expense
Nuvation Bio Inc. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$151.6M
FY2025
5-year range
$24.3M / $151.6M
FY2021-FY2025
Trend
+118.9%
vs FY2024
Sector context
#93 of 213
Health Care
What the data says
At $152M, Nuvation Bio Inc.'s sg&a expense ranks #121 of 213 in the Health Care sector. Increased from $29M to $152M over the past 2 years.
Based on SEC 10-K filings.
$152M in FY2025 with a 5-year CAGR of +69.1%.
Increased from $29M to $152M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +68.1%
- 5-Year CAGR
- +69.1%
- 10-Year CAGR
- -
Sector benchmark
#121 of 213 in Health CareTop 56% of 213This company $151.6M Sector average $722.3M
▼
-79.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +69.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 118.9% year-over-year.
- Ranks #93 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $151.6M | +118.9% |
| FY2024 | $69.2M | +142.6% |
| FY2023 | $28.5M | -10.6% |
| FY2022 | $31.9M | +31.5% |
| FY2021 | $24.3M | +121.8% |
| FY2020 | $10.9M | - |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026